본문영역 바로가기
ABL Bio - medicine for A Better Life
About Us
Who We Are
History
Corporate Identity
Leadership
Contact Us
Platform & Strategies
Platform
Oncology Strategy
CNS Disease Strategy
ADC Strategy
Publications
Pipeline
Overview
ABL301
ABL503
ABL111
ABL102
ABL103
ABL104
ABL105
ABL602
ABL501
Investors & Media
Public Disclosure
Stock Information
Finance Information
Notice
News
Document & Materials
Careers
Core Competencies
Benefits
Recruitment
Recruiting Process
KOR
ENG
모바일 메뉴 보기
Investors & Media
News
Home
Investors & Media
News
[서울경제] 이상훈 에이비엘바이오 대표 "900억 계약금 수령…추가 기술수출 자신있죠"
2022-03-28
ablbio
https://www.sedaily.com/NewsView/263LEWHPPV
list
PREV
ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson’s Disease
NEXT
ABL Bio to receive 6 million milestone payment for ABL001
ABL Bio
About Us
Who We Are
History
Corporate Identity
Leadership
Contact Us
Platform & Strategies
Platform
Oncology Strategy
CNS Disease Strategy
ADC Strategy
Publications
Pipeline
Overview
ABL301
ABL503
ABL111
ABL102
ABL103
ABL104
ABL105
ABL602
ABL501
Investors & Media
Public Disclosure
Stock Information
Finance Information
Notice
News
Document & Materials
Careers
Core Competencies
Benefits
Recruitment
Recruiting Process
메뉴닫기